PMLiVE2d
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
GlobalData on MSN6d
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Healio1d
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
The Pharma Letter2d
Galderma doubles up on Nemluvio approvals
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
Medscape1d
European Commission Approves Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization In The United Kingdom And Switzerland For Moderate-To...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
Armed robbery in Revesby2d
Galderma's Nemluvio Approved in UK, Switzerland
These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...
Yahoo Finance2d
Galderma Group N (GALD.SW)
ZUG, Switzerland, February 14, 2025--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in ...
Morningstar6d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...
Mena FN6d
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
(BUSINESS WIRE )--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU).